SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Jacobsson Lennart T. H. 1954 )
 

Search: WFRF:(Jacobsson Lennart T. H. 1954 ) > Retention and respo...

  • Brahe, C. H. (author)

Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2019-10-30
  • Oxford University Press (OUP),2020

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/295049
  • https://gup.ub.gu.se/publication/295049URI
  • https://doi.org/10.1093/rheumatology/kez427DOI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Objective. To investigate TNF inhibitor (TNFi) retention and response rates in European biologic-naive patients with PsA. Methods. Prospectively collected data on PsA patients in routine care from 12 European registries were pooled. Heterogeneity in baseline characteristics between registries were explored (analysis of variance and pairwise comparison). Retention rates (Kaplan-Meier), clinical remission [28-joint count DAS (DAS28) <2.6; 28 joint Disease Activity index for Psoriatic Arthritis 4] and ACR criteria for 20% improvement (ACR20)/ACR50/ACR70 were calculated, including LUNDEX adjustment. Results. Overall, 14 261 patients with PsA initiated a first TNFi. Considerable heterogeneity of baseline characteristics between registries was observed. The median 12-month retention rate (95% CI) was 77% (76, 78%), ranging from 68 to 90% across registries. Overall, DAS28/28 joint Disease Activity index for Psoriatic Arthritis remission rates at 6 months were 56%/27% (LUNDEX: 45%/22%). Six-month ACR20/50/70 responses were 53%/38%/22%, respectively. In patients initiating a first TNFi after 2009 with registered fulfilment of ClASsification for Psoriatic ARthritis (CASPAR) criteria (n = 1980) or registered one or more swollen joint at baseline (n = 5803), the retention rates and response rates were similar to those found overall. Conclusion. Approximately half of >14 000 patients with PsA who initiated first TNFi treatment in routine care were in DAS28 remission after 6 months, and three-quarters were still on the drug after 1 year. Considerable heterogeneity in baseline characteristics and outcomes across registries was observed. The feasibility of creating a large European database of PsA patients treated in routine care was demonstrated, offering unique opportunities for research with real-world data.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Ornbjerg, L. M. (author)
  • Jacobsson, Lennart T. H.,1954Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research(Swepub:gu)xjacle (author)
  • Nissen, M. J. (author)
  • Kristianslund, E. K. (author)
  • Mann, H. (author)
  • Santos, M. J. (author)
  • Reino, J. G. (author)
  • Nordstrom, D. (author)
  • Rotar, Z. (author)
  • Gudbjornsson, B. (author)
  • Onen, F. (author)
  • Codreanu, C. (author)
  • Lindstrom, U. (author)
  • Moller, B. (author)
  • Kvien, T. K. (author)
  • Pavelka, K. (author)
  • Barcelos, A. (author)
  • Sanchez-Piedra, C. (author)
  • Eklund, K. K. (author)
  • Tomsic, M. (author)
  • Love, T. J. (author)
  • Can, G. (author)
  • Ionescu, R. (author)
  • Loft, A. G. (author)
  • van der Horst-Bruinsma, I. E. (author)
  • Macfarlane, G. J. (author)
  • Iannone, F. (author)
  • Hyldstrup, L. H. (author)
  • Krogh, N. S. (author)
  • Ostergaard, M. (author)
  • Hetland, M. L. (author)
  • Göteborgs universitetInstitutionen för medicin, avdelningen för reumatologi och inflammationsforskning (creator_code:org_t)

Related titles

  • In:Rheumatology: Oxford University Press (OUP)59:7, s. 1640-16501462-03241462-0332

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view